| 1 |
32102624 | In silico search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation. | 2021 Mar |
3 |
| 2 |
31006308 | A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - A drug intended for treatment of brain metastases in non-small cell lung cancer. | 2020 Apr |
1 |
| 3 |
31183631 | Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation. | 2020 Feb |
8 |
| 4 |
31345012 | Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. | 2020 Jan |
4 |
| 5 |
31486987 | Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report. | 2020 Aug |
1 |
| 6 |
31581843 | Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis. | 2020 Mar |
2 |
| 7 |
31648999 | Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. | 2020 Jan |
3 |
| 8 |
32093857 | Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy. | 2020 Mar |
1 |
| 9 |
32093862 | Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC. | 2020 Mar |
1 |
| 10 |
32127933 | Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. | 2020 |
2 |
| 11 |
32129931 | Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. | 2020 Apr |
7 |
| 12 |
32139298 | TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. | 2020 Apr |
3 |
| 13 |
32145595 | Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review. | 2020 Apr |
3 |
| 14 |
32146032 | Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation. | 2020 Jul |
1 |
| 15 |
32154925 | Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer. | 2020 Jun 1 |
7 |
| 16 |
32173232 | Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation. | 2020 Sep |
1 |
| 17 |
32193290 | Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. | 2020 May 15 |
2 |
| 18 |
32200138 | Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). | 2020 May |
2 |
| 19 |
32209253 | Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation. | 2020 May |
1 |
| 20 |
32211870 | Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis. | 2020 Mar 2 |
4 |
| 21 |
32213382 | Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. | 2020 May |
4 |
| 22 |
32216945 | Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib. | 2020 Apr |
1 |
| 23 |
32217611 | Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue. | 2020 Jun 1 |
2 |
| 24 |
32224854 | Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer. | 2020 Mar 26 |
1 |
| 25 |
32231715 | The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. | 2020 |
4 |
| 26 |
32234920 | Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. | 2020 Apr |
2 |
| 27 |
29807405 | Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. | 2019 Jan |
2 |
| 28 |
30111817 | Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. | 2019 Jan |
1 |
| 29 |
30126856 | Osimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. | 2019 Jun |
7 |
| 30 |
30131091 | Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients. | 2019 May 7 |
1 |
| 31 |
30171258 | Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. | 2019 Jan |
3 |
| 32 |
30189719 | A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. | 2019 Apr |
2 |
| 33 |
30230541 | Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients. | 2019 Jan 15 |
2 |
| 34 |
30257889 | Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. | 2019 Mar |
3 |
| 35 |
30302022 | An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC. | 2019 Feb |
2 |
| 36 |
30332963 | Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases. | 2019 |
2 |
| 37 |
30365094 | Osimertinib (AZD9291) increases radio‑sensitivity in EGFR T790M non‑small cell lung cancer. | 2019 Jan |
8 |
| 38 |
30483795 | Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells. | 2019 Feb |
2 |
| 39 |
30500458 | Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. | 2019 Jan |
2 |
| 40 |
30582282 | Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. | 2019 May |
1 |
| 41 |
30588029 | Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. | 2019 |
7 |
| 42 |
30609789 | First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? | 2019 Jan 3 |
5 |
| 43 |
30613959 | Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. | 2019 Jul 1 |
3 |
| 44 |
30639208 | Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China. | 2019 Feb |
3 |
| 45 |
30642539 | Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. | 2019 Jan |
2 |
| 46 |
30642559 | Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. | 2019 Jan |
2 |
| 47 |
30651400 | Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. | 2019 May |
6 |
| 48 |
30651547 | AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. | 2019 Jan 16 |
4 |
| 49 |
30657347 | Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. | 2019 Mar |
3 |
| 50 |
30659024 | Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. | 2019 Apr 1 |
6 |